Type 2 Diabetes – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of T2D for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s T2D forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of T2D?
• Of all people with T2D, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with T2D, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of T2D over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of T2D cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following subpopulations:

• Diagnosed prevalent cases of T2D with CVD by drug-treatment status.
• Drug-treated prevalent cases of T2D by glycemic control status.
• Diagnosed prevalent cases of T2D by glycemic control status.
• Total prevalent cases of T2D by body mass index.
• Total prevalent cases of T2D by diagnosis status.

Note: Coverage may vary by country and region.